BiotechTube
HVR Cardio

HVR Cardio

Helsinki, Finland· Est.
hvrcardio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

HVR Cardio is a private, clinical-stage medical device company pioneering a transcatheter mitral valve repair system called CathHELIX. Its proprietary HELIX technology is designed to perform a percutaneous annuloplasty, addressing the root cause of mitral regurgitation (annular dilation) by deploying a self-securing ring. The company is led by an experienced team with deep roots in structural heart innovation and is supported by a strong clinical advisory board. HVR Cardio is positioned to address a large, underserved market of patients with degenerative mitral regurgitation who are unsuitable for or seek alternatives to open-heart surgery.

Cardiovascular

Technology Platform

Proprietary HELIX technology enabling transcatheter annuloplasty via a self-fixating ring that anchors to both atrial and ventricular sides of the mitral annulus.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The transcatheter annuloplasty market is a major unmet need within the large and growing structural heart sector.
Success could position CathHELIX as a first-line, foundational repair therapy for mitral regurgitation, appealing to a broad patient population and potentially enabling combination therapies.
The experienced leadership and strong clinical connections provide a solid foundation for clinical development and future partnership or acquisition.

Risk Factors

High technical and clinical risk in developing a safe, effective, and durable percutaneous annuloplasty device.
Intense competition from large medtech players and well-funded startups also targeting transcatheter mitral repair.
Significant regulatory hurdles and capital requirements to reach commercialization in a space dominated by established competitors.

Competitive Landscape

HVR Cardio operates in the highly competitive transcatheter mitral valve repair (TMVR) space, competing directly with large players like Abbott (MitraClip, TriClip) and Edwards Lifesciences (PASCAL), which currently dominate with leaflet repair devices. Its primary competitors are other companies developing transcatheter annuloplasty systems, such as Medtronic, Cardiovalve, and Mitralign. Success will depend on demonstrating superior safety, efficacy, and ease of use compared to these emerging and established technologies.

More companies in Regenerative Medicine →More companies in Finland →